Author Archives: Bruno Quinney

Mycobacterium tuberculosis bacteria.
#Protein #TB vaccine #Tuberculosis

TB vaccine could target several proteins, MIT study shows 

A new study by the Massachusetts Institute of Technology (MIT) has revealed new targets for a tuberculosis (TB) vaccine.  A large-scale screen of tuberculosis proteins highlighted several possible antigens that could be developed as a new vaccine for TB, the world’s deadliest infectious disease.  A team of… Read More

#News

The tumour microenvironment
#Cancer research #Immunotherapy #Solid tumours

MaaT Pharma releases positive results for anti-tumour candidate 

Biotechnology company MaaT Pharma has announced preclinical results for its drug candidate MaaT034, including promising anti-tumour efficacy results and immune activation.  MaaT034, a first-in-class co-cultured full ecosystem product, is designed to optimise intestinal microbiome functions and improve patient responses to immunotherapy in combination with Immune Checkpoint Inhibitors (ICIs).   The… Read More

#Cancer Research #News

Pancreatic cancer
#Cancer research #Leukaemia #Oncology #Proteomics

Discovery of ‘handbrake’ enzyme offers cancer breakthrough 

Researchers have discovered a ‘handbrake’ mechanism controlling how cells respond to cancer drugs, which could reshape understanding of cancer drug resistance.  The breakthrough research, led by scientists from the University of Oxford and the Research Centre for Molecular Medicine, Austria, demonstrates how the enzyme NUDT5 acts as a molecular… Read More

#Cancer Research #News

International Space Station (ISS)
#Data #Drug design #Drug discovery #GlobalData

Defying gravity: Space emerges as ‘laboratory for innovation’  

Space manufacturing could become a platform for scientific discovery and biomedical advancement, according to analytics company GlobalData.  Analysis from GlobalData suggests environments in space are increasingly accessible, with pharmaceutical and biotech companies focusing on low-Earth orbit to explore new opportunities. This includes advancing drug development,… Read More

#News

CAR-T therapy for leukaemia
#Acute Myeloid Leukaemia #Bioengineering #Cancer research #CAR T-cell therapy

Researchers use first non-animal model in AML research 

Scientists have successfully used the first bioengineered bone marrow model to carry out cancer research, offering a new method which does not rely on animal models.  The breakthrough, made by researchers at the University of Glasgow, represents an important step forward in being able to uncover insights into leukaemia without the… Read More

#Cancer Research #News

#Bacteria #Genome sequencing #Vaccines

Vaccine could be developed for H. influenzae bacteria, study shows 

Scientists believe a vaccine could be developed to tackle Haemophilus influenzae (H. influenzae) bacteria, which causes up to 200 million childhood infections each year.  An international team including researchers at the Wellcome Sanger Institute, the University of Oslo, the University of Oxford and the Shoklo Malaria Research Unit at Mahidol University in Thailand, found… Read More

#News

#RNA #SPT Labtech #Transcriptomics

Alithea Genomics partners with SPT Labtech on transcriptomics 

Biotechnology company Alithea Genomics has announced a collaboration with manufacturer SPT Labtech to provide an automated solution for single-cell transcriptomics.   The collaboration integrates Alithea Genomics’ ultra-sensitive single-cell RNA-seq technology, MERCURIUS FLASH-seq, with SPT Labtech’s firefly liquid handling platform, which the companies say will create a scalable and reproducible workflow for transcriptomics research. Read More

#Business & Investment #News

#Biotechnology

Slingshot Therapeutics announces board appointments

Biotechnology company Slingshot Therapeutics, part of the Syncona Accelerator, has appointed John Isaac as Chief Scientific Officer and Bobby Soni as Chief Business Officer.  Isaacs will be responsible for the company’s scientific strategy, progress across the pipeline, and delivery of therapeutic assets. He will also lead the identification, technical assessment and selection of early-stage drug… Read More

#News

Cancer cells
#Antibody drug conjugate (ADC) #Circulating tumour cell enumeration #Oncology

Results show CTCs could be ‘dynamic biomarkers in oncology’

CellBxHealth, the company specialising in circulating tumour cell (CTC) solutions, has presented encouraging results on cell visualisation and biomarker analysis, which could shape antibody-drug conjugate (ADC) therapy.  The results, presented at the World ADC conference in San Diego, US, demonstrate successful cell visualisation and biomarker analysis across ADC targets… Read More

#Cancer Research #News

Mosquito
#Australia #Vaccines #Virology

New research paves way for yellow fever vaccine development 

Researchers have captured the first-ever high-resolution images of yellow fever virus (YFV), which could pave the way for vaccine design.  Scientists at the University of Queensland, Australia, revealed structural differences between the vaccine strain (YFV-17D) and the virulent, disease-causing strains of the virus. Researchers combined yellow fever’s structural… Read More

#News

Human data concept
#Data #Drug discovery #Oncology #Spatial biology #The Francis Crick Institute

How is spatial biology rewriting the rules of oncology drug discovery?

Diana Turner explores how Nature’s 2024 ‘Method of the Year’ is transforming our understanding of cancer.    Invented in the early 2000s, spatial biology is a technique revealing unique insights into biomolecules and how they interact within their cellular and tissue architecture. As a result, and as technologies advance in accuracy, there is increasing industry interest and adoption for uses of spatial biology in… Read More

#Exclusive Content

#Antibody drug conjugate (ADC) #Drug discovery #Manufacturing

Tackling ADC development 

DDW Editor Reece Armstrong speaks to Francisca Neethling, Head of Biotherapeutic Services and Olivier Mirguet, Global Head of Chemistry, at Eurofins Discovery about the challenges of antibody drug conjugate drug discovery and development and how strategies have evolved over time for these important therapies.     RA: What are some common challenges developers are facing with ADC development?   FN… Read More

#Exclusive Content

Duchenne muscular dystrophy
#Duchenne muscular dystrophy #Gene editing #Gene mutation #Gene therapy

Duchenne UK hands out £500,000 award to develop DMD therapy 

Duchenne UK has awarded £500,000 ($653,000) to biotech company MyoGene Bio to support the development of an innovative gene editing therapy for Duchenne muscular dystrophy (DMD).  The funding is part of Duchenne UK’s Therapeutic Call, a competitive initiative designed to support innovative research with the potential to deliver new treatments for DMD.  MyoGene Bio… Read More

#Business & Investment #News

T cells
#Genetics #Sonoma Biotherapeutics #T cell

SonomaBio receives $300,000 grant to develop T-cell therapies 

Biotechnology company Sonoma Biotherapeutics has received a $300,000 G-Rex Grant to expedite the production of gene-modified regulatory T-cell therapies.  The grant was awarded by gene therapy manufacturer ScaleReady, aiming to advance the state of cell and gene-modified cell therapy development.   SonomaBio will now expedite the development of a G-Rex-based manufacturing process to develop T-cell (Treg) therapies… Read More

#Business & Investment #News

#Automation / robotics #Data automation #Lab technology #Pistoia Alliance

What labs can learn (and can’t) from automation in other industries

Dr Patrick Courtney, Member of Board of Directors of SiLA, compares the uptake of automation in industries other than drug discovery.     In our industry we’re often deep in our day-to-day work, but once in a while someone will ask a question that stimulates us to look outside and see how other industries are dealing with the challenges… Read More

#Exclusive Content

Mitochondria
#FDA #Mitochondria

FDA approval of first TK2d drug offers ‘hope for the future’ 

The US Food and Drug Administration (FDA) has approved the first treatment for thymidine kinase 2 deficiency (TK2d), paving the way for landmark treatment options for the mitochondrial disease.  Doxecitine and doxribtimine, approved by the FDA, are oral solutions developed by biopharmaceutical company UCB. The powder, also known as Kygevvi, has been approved… Read More

#News